Furthermore, although currently there is no evidence that TET1 levels in TNBC could be used as a biomarker to predict response to immunotherapy, there is emerging evidence that TET1 mutant samples in several cancers were more immunogenic and showed better responses to immune checkpoint inhibitors [88]. The gene discussed is TET1; the disease is cancer.